Literature DB >> 29137425

A fatal case of mitochondrial DNA depletion syndrome with novel compound heterozygous variants in the deoxyguanosine kinase gene.

Weiyuan Fang1, Peng Song2,3, Xinbao Xie1, Jianshe Wang1, Yi Lu1, Gang Li4, Kuerbanjiang Abuduxikuer1.   

Abstract

The deoxyguanosine kinase (DGUOK) gene controls mitochondrial DNA (mtDNA) maintenance, and variation in the gene can alter or abolish the anabolism of mitochondrial deoxyribonucleotides. A Chinese female infant, whose symptoms included weight stagnation, jaundice, hypoglycemia, coagulation disorders, abnormal liver function, and multiple abnormal signals in the brain, died at about 10 months old. Genetic testing revealed a compound heterozygote of alleles c.128T>C (p.I43T) and c.313C>T (p.R105*) of the DGUOK gene. c.128T>C (p.I43T) is a novel variant located in exon 1 (NM_080916) in the first beta sheet of DGUOK. Her mother was an allele c.313C>T (p.R105*) heterozygote, which is located in DGUOK exon 2 (NM_080916) between the third and fourth alpha helixes. c.313C>T (p.R105*) is predicted to result in a 173 amino acid residue truncation at the C terminus of DGUOK. There are as many as 112 infantile mtDNA depletion syndrome (MDS) cases in the literature related to DGUOK gene variants. These variants include missense mutations, nucleotide deletion, nucleotide insertion, and nucleotide duplication. Integrated data showed that mutations affected both conserved and non-conserved DGUOK amino acids and are associated with patient deaths.

Entities:  

Keywords:  deoxyguanosine kinase (DGUOK); mitochondrial DNA depletion syndrome (MDS)

Year:  2017        PMID: 29137425      PMCID: PMC5663597          DOI: 10.18632/oncotarget.20905

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


INTRODUCTION

Mitochondrial DNA (mtDNA) is a 16.6 kb circular double-stranded DNA encoding the protein subunits of mitochondrial respiratory chain complexes I, III, IV, and V and which functions in energy production [1, 2]. All of the mtDNA replication, transcription factors, and the primary components of the mitochondrial translation machinery are encoded by nuclear genes [1, 2]. Mutations in nuclear genes that function in either mitochondrial deoxyribonucleoside triphosphate (dNTP) synthesis or mtDNA replication can lead to a severe reduction in cellular mtDNA content in affected organs, which is termed mtDNA depletion syndrome (MDS) [1, 2]. Thymidine kinase 2, adenosine diphosphate-forming succinyl CoA ligase beta subunit, guanosine diphosphate-forming succinyl CoA ligase alpha subunit, ribonucleotide reductase M2 B subunit, thymidine phosphorylase, and deoxyguanosine kinase (DGUOK) encode proteins that maintain the mitochondrial dNTP pool, and mutations in any of these genes can result in mtDNA depletion [2]. DNA polymerase gamma and Twinkle are essential for mtDNA replication, and mutations in these genes can result in inadequate mtDNA synthesis [2]. Clinically, MDS is classified into myopathic, encephalomyopathic, neurogastrointestinal, and hepatocerebral forms that are associated with mutations in the above genes [2]. Of the four forms of MDS, hepatocerebral MDS is associated with DGUOK gene mutations and occurs during the neonatal period [2-31]. The common clinical features of hepatocerebral MDS include hepatic dysfunction, psychomotor delay, hypotonia, rotary nystagmus developing into opsoclonus, lactic acidosis, and hypoglycemia [2-31]. Here, we report a fatal case of MDS with a novel compound heterozygous mutation in the DGUOK gene as well as a systemic literature review.

RESULTS

Clinical findings

Physical examination at 9 months and 4 days of age revealed slight jaundice, with a head circumference, chest circumference, height, weight, temperature, heart rate, and respiration rate of 40.0 cm, 41.0 cm, 69.0 cm, 7.0 kg, 37.2°C, 134 beats per minute, and 32 times per minute, respectively (Table 1). No obvious psychomotor delay, hypotonia, or rotary nystagmus was observed. Visual inspection and palpation found no obvious abnormalities except for splenomegaly.
Table 1

Clinical and laboratory findings

Personal history
 Age9 months and 4 days
 Gravidity (G) and Parity (P)G3P1
 Gestation37 weeks+2days
 Birth weight (g)2,550
 Birth historyBreech position caesarean section
Family history
 Pregnancy history of mother1-0-2-1
Physical examination
 Head circumference (cm)40.0
 Chest circumference (cm)41.0
 Height (cm)69.0
 Weight (kg)7.0
 Temperature (°C)37.2
 Heart rate (beats per minute)134.0
 Respiration rate (times per minute)32.0
Biochemical examination
 Albumin (g/L)25.0–33.7*
 Alanine aminotransferase, ALT (IU/L)77.0–293.0
 Glutamate oxalacetate transaminase, GOT (IU/L)203.0–623.0
 Direct bilirubin (umol/L)24.4–265.0
 Total bilirubin (umol/L)213.5–340.8
 Alpha fetal protein (ng/mL)29,090–121,000
 Lactic acid (mmol/L)2.1–5.4
 Glucose (mmol/L)1.44–4.10
 Ammonia (umol/L)80.0–130.0
Coagulation test
 D-dimer (mg/L)0.49–20.0
 Activated partial thromboplastin time (s)> 180
 Thrombin time (s)23.0–42.8
 Prothrombin time (s)39.2–75.9
 Fibrinogen (g/L)0.6
Blood routine examination
 Hemoglobin (g/L)111.0–115.0
 Red blood cell count (per liter)3.2–3.9 × 1012
 White blood cell count (per liter)14.3 × 109
 Lymphocytes (%)38.7–52.5
 Neutrophils (%)35.4–50.0
 Platelets count (per liter)146–479 × 109
Blood gas analysis
 pH7.45
 pCO2 (mmHg)32.80
 pO2 (mmHg)43.60

*Multiple test results are presented as (25.0–29.7).

*Multiple test results are presented as (25.0–29.7). Biochemical examination revealed hepatic dysfunction, lactic acidosis, and hypoglycemia. The serum levels of albumin, alanine aminotransferase, glutamate oxalacetate transaminase, direct bilirubin, total bilirubin, lactic acid, and glucose were 25.0–33.7 g/L (normal range: 60–83 g/L), 77.0–293.0 IU/L (normal range: 0–40 IU/L), 203.0–623.0 IU/L (normal range: 0–40 IU/L), 24.4–265.0 umol/L (normal range: 0–6 umol/L range), 213.5–340.8 umol/L (normal range: 5.1–17.1 umol/L), 2.1–5.4 mmol/L (normal range: <1.8 mmol/L), and 1.44–4.10 mmol/L (normal range: 3.9–5.8 mmol/L), respectively (Table 1). Biochemical tests also showed extremely high alpha fetal protein 29,090–121,000 ng/mL (normal range: 0 -77 ng/mL) and elevated ammonia 80.0–130.0 umol/L (normal range: 10–47 umol/L). Coagulation tests showed dysfunctional blood clotting. The D-dimer, activated partial thromboplastin time, thrombin time, prothrombin time, and fibrinogen were 0.49–20.0 mg/L (normal range: 0.0–0.3 mg/L), >180 s (normal range: 28.0–44.5 s), 23.0–42.8 s (normal range: 14.0–21.0), 39.2–75.9 s (normal range: 12.0–14.8 s) and 0.6 g/L (normal range: 2.0 -4.0 g/L), respectively (Table 1). Blood gas analysis showed that pH, pCO2, and pO2 were 7.45 (normal range: 7.35–7.45), 32.80 mmHg (normal range: 35.0–45.0 mmHg), and 43.60 mmHg (normal range: 80 -100), respectively (Table 1). Abdominal ultrasonography showed multiple focal liver lesions, hepatic fibrosis, and massive ascites. Brain magnetic resonance imaging (MRI) showed higher DWI and T2WI signals in the bilateral frontal, temporal, parietal, and occipital lobes, the corpus callosum, internal and external capsules, and the brain stem (Figure 1A). In addition, a high T2WI signal also was observed in the bilateral globus pallidus (Figure 1A). Proton magnetic resonance spectroscopic imaging showed normal N-acetylaspartate, choline and creatine peaks in the basal ganglia and thalamus. The results suggested that the patient had hepatocerebral MDS and was thus given symptomatic and supportive treatment for eight days in our hospital. The girl died one and a half months after release from the hospital.
Figure 1

Brain MRI and DGUOK structure

(A) Brain MRI. T1WI, T1 weighted image; T2WI, T2 weighted image; TIRM, turbo inversion recovery magnitude; DWI, diffusion-weighted magnetic resonance imaging. (B) Structure-based sequence alignment of the human DGUOK gene (SwissProt Q16854). The numbers refer to the DGUOK amino acid sequence. Red characters refer to the conserved substrate-binding site. Black fields represent residues identical to the sequences of deoxycytidine kinase, thymidine kinase 2, and deoxyribonucleoside kinase.

Brain MRI and DGUOK structure

(A) Brain MRI. T1WI, T1 weighted image; T2WI, T2 weighted image; TIRM, turbo inversion recovery magnitude; DWI, diffusion-weighted magnetic resonance imaging. (B) Structure-based sequence alignment of the human DGUOK gene (SwissProt Q16854). The numbers refer to the DGUOK amino acid sequence. Red characters refer to the conserved substrate-binding site. Black fields represent residues identical to the sequences of deoxycytidine kinase, thymidine kinase 2, and deoxyribonucleoside kinase.

Genetic findings

Genetic testing revealed that this girl was a compound heterozygote for DGUOK gene alleles c.128T>C (p.I43T) and c.313C>T (p.R105*) (Table 2). Her father was a heterozygous carrier of allele c.128T>C (p.I43T). c.128T>C (p.I43T), a novel variant located in exon 1 (National Center for Biotechnology Information ID: NM_080916) that encoded an amino acid in the first beta sheet of the DGUOK protein (Table 2 and Figure 1B). c.128T>C (p.I43T) has been included in the Human Gene Mutation Database, the NHLBI GO Exome Sequencing Project, or the 1000 Genomes Project to date, and has not been previously reported (Table 2). The patient's mother was a heterozygous carrier of allele c.313C>T (p.R105*). c.313C>T (p.R105*) is located in exon 2 (NM_080916) and encodes amino acids located in the third and fourth alpha helixes of the DGUOK protein (Table 2 and Figure 1B). c.313C>T (p.R105*) is predicted to result in a 173 amino acid residue truncation at the C terminus of the DGUOK protein [18]. No prior cases of MDS were found in the family histories of either parent.
Table 2

Cumulative frequencies of reported variants of DGUOK gene

Ethnicity / NationalityVariantsZygotic typeSexConsanguinitySourceDeathReference
DGUOK mutations in children with MDS
Chinesec.128T>C(p.I43T)/c.313C>T(p.R105*)CHFNoHPYesthis report
French?c.2T>C(p.M1T)HomozygoteFNoHPYes4
French?c.2T>C(p.M1T)HomozygoteFNoHPYes5
Italian?c.2T>C(p.M1T)/c.677A>G (p.H226R)CHM???6
Polish?c.3G>A(p.M1I)/c.813_814insTTT(p.N271_T272insF)CHF??Yes7
Polish?c.3G>A(p.M1I)HomozygoteF??Yes7
Turkishc.34C>T(p.R12X)Homozygote?Yes?Yes8
Hispanicc.80delC/c.763_c766dupGATTCHFNo?Yes9
Turkish?c.130G>A(p.E44K)HomozygoteM2YesHPYes11
French?c.137A>G(p.N46S)HomozygoteMNo??5
American?c.137A>G(p.N46S)/c.352C>T(p.R118C)CHMNoHPYes13
American?c.137A>G(p.N46S)/c.352C>T(p.R118C)CHM2NoHP4y (2009)13
Hispanicc.137A>G(p.N46S)/c.352C>T(p.R118C)CHM??Yes9
Japaneseg.11692_12026del335(p.A48fsX90)HomozygoteF2No?Yes14
Japaneseg.11692_12026del335(p.A48fsX90)HomozygoteFNo?Yes14
Germanc.155C>T(p.S52F)HomozygoteMYes?1y (2006)3
Russianc.155C>T(p.S52F)/c.681-684delGTTTCHF2No?Yes3
Europeanc.165G>A(p.W65X)/c.487_c490dupGACACHM2??Yes9
Israeli-Druzec.204del AHomozygoteM5F15YesHP19 died15
Arabsc.223T>A(p.W75R)HomozygoteF??Yes16
Lebanesec.235C>T(p.79*)HomozygoteF2Yes?Yes9,17
Germanc.313C>T (p.R105*)HomozygoteMNoHPYes18
French?c.313 C>T (p.R105*)HomozygoteMNo?Yes5
Indianc.318 G>A (p.W106*)?FNo?Yes9,17
Europeanc.352C>T(p.R118C)HomozygoteFNoMUDYes19
Italianc.444-11C>G/c.605_c.606delGACHM??Yes9
Turkish?c.493G>A(p.E165K)HomozygoteMYes?Yes11
Polish?c.494A>T(p.E165V)HomozygoteM??Yes7
French?c.495A>T(p.E165V)/P246RCHMNo??5
Turkishc.509A>G(p.Q170R)HomozygoteFNoHP2y (2006)3
French?c.591A>G/nt424_425delAGCHMNo??5
Hispanicc.533G>A(p.W178X)HomozygoteFNoPUIYes9
American?c.533G4A (p.W178X)Homozygote?NoPUIYes21
African Americanc.572A>G(p.Y191C)HomozygoteFNoHPYes22
Chinesec.572A>G(p.Y191C)/c.151A>C(p.K51Q)CHF??Yes9
Frenchc.4G>T(p.A2S)/c.591G>ACHMNoHPYes23
Caucasian/Hispanicc.605_c606 delGA/c.591G>A (p.Q197Q)CHF??Yes9
Mexicanc.592-4_c.592-3delTTHomozygoteFYesHPYes24
Mexicanc.592-4_c.592-3delTTHomozygoteFYesHP?24
Italian?c.delGA603_604(p.K201fs214X)HomozygoteM??Yes6
American?c.609_c.610delGTHomozygoteF2??Yes20
Arabsc. 617G>A(p.R206K)HomozygoteFYesHPYes16
Hispanicc.677A>G(p.H226R)/c.592-4_c.592-3delTTCHM??Yes9
Caucasianc.677A>G (p.H226R)HomozygoteM1F1Yes?Yes25
American?c.707+417(intron 5)/c.834 (end of 3’UTR)+3416, del3127bpHomozygoteF??Yes26
French?c.721_724insTGAT+HomozygoteM??Yes5
Italian?c.749T>C(p.L250S)HomozygoteF??Yes6
French?c.749T>C(p.L250S)HomozygoteM1F1YesHPYes4
Italianc.749T>C(p.L250S)HomozygoteFNo?Yes27
French?c.749T>C(p.L250S)HomozygoteFYes??5
Portuguese?c.749T>C(p.L250S)HomozygoteMYes?Yes25
Portuguesec.749T>C(p.L250S)/c.1A>G(p.M1T)CHM/FNoHPYes3
French?IVS2nt-2/c.749T>C(p.L250S)CHF??Yes5
American?c.763_766dupGATTHomozygoteF2YesHPYes20
Moroccanc.763_766dupGATTHomozygoteFYes?Yes28
Moroccanc.763_766dupGATTHomozygote???Yes23
Moroccanc.763_766dupGATTHomozygoteM2F1YesHPYes29
Algerianc.763_766dupGATTHomozygoteM2NoHPYes29
Moroccanc.763_766dupGATTHomozygoteFYesHP?29
Italian?c.763_766dupGATT/c.130g>A(p.E44K)CHF??10mo (2002)6
Mennonitec.763G>T (p.D255Y)HomozygoteM1F1?HPYes30
Arabsc.766_767insGATT(p.F256*)HomozygoteM2??Yes16
Polish?c.766_767insGATT(p.F256X)HomozygoteF??Yes7
French?c.633A>G(p.E211G)/c.797T>G(p.L266R)CHMNo?Yes4
French?c.495A>T(p.E165V)/c.797T>G(p.L266R)CHMNo?Yes4
French?c.495A>T(p.E165V)/c.797T>G(p.L266R)CHMNo?Yes5
Tunisianc.444-62C>AHomozygoteMYesHPYes31
Moroccanc.444-62C>AHomozygoteM2YesHPYes31
Turkish?c.707+3_6delTAAGHomozygoteFYesHPYes11
Cases of reversible MDS
Frenchc.137A>G (N46S)/c.797T>G(p.L266R)CHMNoHP10y (2007)23
American?c.81_c.82insCC(p.S28P)/c.4G>T (p.A2S)CHM??21y (2012)10
Italianc.319T>C (p.S107P)HomozygoteM??3.5y (2007)9
Hispanicc.137A>G(p.N46S)/c.352C>T(p.R118C)CHM??3.5y (2007)9
Cases of MDS underwent liver transplantation
American?c.425G>A(p.R142K)/c.679G>A(p.E227K)CHMNoHP5y (2002)20
Polishc.1A>G(p.M1V)/c.3G>A(p.M1I)CHFNo?1y (2006)3
Mennonitec.763G>T (p.D255Y)HomozygoteF?HP3y (2005)30
DGUOK mutations in adult patients with mitochondrial DNA multiple deletions
Italian?c.130G>A(p.E44K)/c.462 T>A(p.N154K)CHF??72y12
Italian?c.186 C>A(p.Y62*)/c.509A>G(p.Q170R)CHM??80y12
Italian?c.444-11C>G/c.509A>G(p.Q170R)CHF1M1??46y,48y12
Italian?c.605_606delGA(p.R202YfsX12)/c.462T>A(p.N154K)CHF??69y12
Italian?c.605_606delGA(p.R202YfsX12)/c.137A4G p.N46SCHF??23y12

?, unspecified; CH, compound heterozygote; HP, heterozygous parents; PUI, paternal uniparental isodisomy; MUD, maternal uniparental disomy; M5F15, 5 males and 15 females in a single kindred; 72y, 72 years old when data collected; 10mo, 10 months old when data collected; 4y (2009), 4 years old in the published year. Cases with confirmed improvement in the pathological manifestation of MDS were sorted in “Cases of reversible MDS”. Three cases of MDS with liver transplantation were collected together in section of “Cases of MDS underwent liver transplantation”.

?, unspecified; CH, compound heterozygote; HP, heterozygous parents; PUI, paternal uniparental isodisomy; MUD, maternal uniparental disomy; M5F15, 5 males and 15 females in a single kindred; 72y, 72 years old when data collected; 10mo, 10 months old when data collected; 4y (2009), 4 years old in the published year. Cases with confirmed improvement in the pathological manifestation of MDS were sorted in “Cases of reversible MDS”. Three cases of MDS with liver transplantation were collected together in section of “Cases of MDS underwent liver transplantation”.

Demographic and genetic characteristics of cumulative variants of the DGUOK gene

To map the DGUOK gene mutations to MDS, we collected all reports published in the NCBI database (Table 2). In total, 112 infantile MDS cases had been reported worldwide by the end of April 2017. The reports consisted of 60 (53.6%) females and 49 (43.8%) males; 92 (82.1%) died before 1 year of age; 13 (11.6%) subjects were alive when the study was published [3, 6, 9, 10, 13, 15, 20, 23, 30]; 47 (42.0%) and 35 (31.3%) cases were consanguineous offspring and non-consanguineous offspring, respectively (Table 2); 81 (72.3%) and 31 (27.7%) were homozygotes and compound heterozygotes, respectively (Table 2); and the parents of 55 (49.1%) cases were heterozygous carriers of related DGUOK variants (Table 2). Three reviewed MDS cases underwent liver transplantation at age 5, 1, and 3 years old in 2002, 2006, and 2005, respectively (Table 2) [3, 20, 30]. There were four reversible MDS cases, and the pathological manifestation of the four cases was confirmed to be improved [9, 10, 23]. The ages of the patients with reversible cases were 10, 21, 3.5, and 3.5 years old in 2007, 2012, 2007, and 2007, respectively (Table 2). It is difficult to find reversible MDS specific variants in the existing data. Although c.319T>C (p.S107P) was found in an Italian reversible MDS case [9], other variants including c.137A>G (N46S), c.797T>G(p.L266R), c.4G>T (p.A2S), c.137A>G(p.N46S), and c.352C>T(p.R118C) were also found in fatal cases (Table 2). One previous study has reported DGUOK mutations in adults [12]. The subjects ranged in age from 23 to 80 years old. Clinical presentations were variable, and included mitochondrial myopathy with or without progressive external ophthalmoplegia, recurrent rhabdomyolysis, and adult-onset lower motor neuron syndrome with mild cognitive impairment [12]. The genotypes of six individuals in that study were c.130G>A/c.462T>A, c.186C>A/c.509A>G, c.444–11C>G/c.509A>G, c.605_606delGA/c.462T>A, and c.605_606delGA/c.137A>G (Table 2). As the authors indicated, the mutations identified in adults were associated with an infantile hepatocerebral form of MDS [12]. It is also difficult to find adult mtDNA multiple deletion-specific variants. Taken together, these studies suggest that DGUOK variants can occur anywhere in the DGUOK gene, and that it remains difficult to find reversible MDS-specific or adult mtDNA multiple deletion-specific variants.

DISCUSSION

MDS is an autosomal recessive disorder. In this report, we describe a fatal MDS case with novel compound heterozygous variants of the DGUOK gene, c.128T>C(p.I43T)/c.313C>T(p.R105*). To date, two additional reports have described the c.313C>T(p.R105*) variant [5, 18]. The patients in which these mutations were found were both boys, and one was from Germany and one was suspected to be French. Both boys died before 1 year of age. c.313C>T is predicted to result in a truncated DGUOK protein lacking the 173 amino acid residue at the C terminus. c.128T>C (p.I43T) is a novel variant. Because the girl died before reaching 1 year of age, this allele is likely also lethal. Thus, this finding should be considered during pre-pregnancy checkups. During the data-collection process, we found that variants of the DGUOK gene were varied. As shown in Table 2, all types of genetic variants could be found in the DGUOK gene. Missense mutations [3–13, 15–23, 25, 27, 30, 31] can change highly conserved amino acids [3, 20, 23], affect start codon recognition by the ribosome [7, 10, 23], substitute a nonpolar neutral amino acid with a polar one [16], result in a premature stop codon [5, 12, 17, 18], affect the initial methionine [3], or induce splicing anomalies [23]. Nucleotide deletions [3, 5, 6, 9, 11, 12, 14, 15, 20, 24, 26] can lead to frameshift mutations, which could result in either a premature termination of translation [3, 12, 15, 20, 26] or aberrant splicing [24]. Nucleotide insertions [5, 7, 10, 16] can either change the polarity of an amino acid [10] or lead to a premature termination [10, 16]. Finally, nucleotide duplications [6, 9, 20, 23, 28–30] can produce a frameshift mutation, a premature stop codon [9, 20, 28], or induce mRNA instability due to nonsense mutations [15, 30]. The DGUOK protein consists of five beta sheets and nine alpha helixes (Figure 1B) [32]. Nine amino acids make up a conserved substrate-binding site, and 45 amino acids are identical to deoxycytidine kinase, thymidine kinase 2, and deoxyribonucleoside kinase (Figure 1B) [32]. Although previous reports have shown that some variants change highly conserved amino acids [3, 4, 9, 16, 20, 23], integrated data show that mutations are not confined to these conserved sites. Many variants occur outside of the conserved region [3–9, 11–13, 19, 21, 25, 27, 30]. Hepatocerebral MDS always leads to hepatic failure and a variable neurological phenotype [1-3]. Our patient manifested jaundice, hepatosplenomegaly, abnormal hepatic function, and multiple abnormal signals in the brain. It is worth mentioning that the alpha-fetoprotein levels in all reports was extremely high [7, 11, 16]. In our patient, levels were as high as 29,090 ng/mL, which may occur due to the liver regeneration process or the early onset of hepatocellular carcinoma. Since the first report of MDS by Moraes et al. in 1991 [1], the number of cases has increased, and now stand at more than 100. There is confusion in the position and nomenclature of MDS-related DGUOK variants, and many studies have either not provided a reference sequence or have adopted different sequence nomenclature. In Table 2, we list the original expression of variants. A pathogenic map of the DGUOK gene needs to be created. Therefore, it is important to follow Human Genome Variation Society (http://varnomen.hgvs.org) recommendations to standardize the location and nomenclature of MDS-related DGUOK variants going forward. The main limitation to this study is that the patient was critically ill, which prevented us from performing biopsies for complete respiratory chain analysis and mtDNA quantification. Therefore, we were unable to provide any molecular evidence regarding the influence of the c.128T>C(p.I43T) variant on DGUOK expression or activity. In conclusion, our report shows that diversified DGUOK variants can occur anywhere in the DGUOK gene, and that mutations affect both conserved and non-conserved DGUOK amino acids are associated with fatalities.

MATERIALS AND METHODS

This study was approved by the Research Ethics Committee of Children's Hospital of Fudan University and was conducted under the Declaration of Helsinki ethical principles for medical research involving human subjects. Informed consent was obtained from the child's parents.

Patient

A Chinese girl, aged 9 months and 4 days, visited our hospital on February 17, 2016, due to jaundice. The patient was a gravidity 3 and parity 1 (G3P1) infant of unrelated parents. The mother was 31 years old and had three pregnancies, with pregnancy terminations occurring at 1 and 3 months due to fetal growth arrest. The father was 32 years old. The patient was delivered by cesarean section at 37 weeks and 2 days due to a breech position, and had a birth weight of 2,550 g. Eight days after birth, she was hospitalized due to recurrent hypoglycemia (1.0–4.1 mmol/L). Physical and laboratory examinations found jaundice, coagulation disorders, and abnormal liver function. After her release from the hospital, the patient visited multiple hospitals for jaundice, weight stagnation, hepatomegaly, and abnormal liver function. Clinical laboratory and imaging examinations were performed in the corresponding clinical departments in our hospital.

DGUOK gene detection

During multiple hospitalizations, the patient was screened by whole exome sequencing (WES) and multi-gene panels on several occasions to find risk gene variants. WES was performed by an authorized independent gene testing company (Jinyu, Changsha, China). The testing process is briefly described as follows: WES was initiated by preparing a library using 3 μg purified DNA; enrichment was achieved using the SOLiDoptimized Sure Select All Human Exon Kit (Agilent, Technologies, Santa Clara, CA); sequencing was performed using 5500XL sequencers (Life Technologies, Carlsbad, CA). Quality control parameters were strictly observed throughout the WES workflow, and samples failing quality testing were either restarted completely or restarted from an earlier point. Sequence reads were aligned to hg19 using Lifescope v2.1 software (Life Technologies, Shanghai, China) followed by variant analysis of the aligned sequence. Variants were annotated using a custom analysis pipeline. A minimum of 30×median coverage per sample was required for sufficient data quality. In our hospital, rare diseases in pediatrics are further screened using an in-house multi-gene panel [33, 34]. The panel included the following 40 genes: ATPase phospholipid transporting 8B1, ATP binding cassette subfamily B member 11, ATP binding cassette subfamily B member 4, tight junction protein 2, bile acid-CoA: amino acid N-acyltransferase, claudin 1, hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7, Aldo-Keto reductase family 1 member D1, cytochrome P450 family 7 subfamily B member 1, alpha-methylacyl-CoA racemase, cytochrome P450 family 27 subfamily A member 1, 7-dehydrocholesterol reductase, jagged 1, Notch 2, solute carrier family 25 member 13, DGUOK, MPV17, mitochondrial inner membrane protein, fumarylacetoacetate hydrolase, ATP binding cassette subfamily C member 2, UDP glucuronosyltransferase family 1 member A1, NPC intracellular cholesterol transporter 1, NPC intracellular cholesterol transporter 2, galactose-1-phosphate uridylyltransferase, UDP-galactose-4-epimerase, aldolase fructose-bisphosphate A, aldolase fructose-bisphosphate B, keratin 18, keratin 8, UTP4 small subunit processome component, cystic fibrosis transmembrane conductance regulator, glutamyl-TRNA synthetase 2 mitochondrial, hydroxysteroid 17-beta dehydrogenase 4, lipase A lysosomal acid type, peroxisomal biogenesis factor 1, peroxisomal biogenesis factor 5, POU class 1 homeobox 1, HESX homeobox 1, serpin family A member 1, VPS33B interacting protein, apical-basolateral polarity regulator, Spe-39 homolog, and late endosome and lysosome associated VPS33B. Other than DGUOK, no variants in any of the above genes were found. The DGUOK gene variants were further confirmed by Sanger sequencing using DNA from peripheral blood leukocytes.

Literature search

To understand the relationships between MDS and DGUOK gene variants, we systematically searched all published studies in PubMed. The latest published data were updated in April 2017. The following terms were used to search titles and abstracts: (mitochondrial DNA depletion syndrome or MDS or OMIM 251880) and (deoxyguanosine kinase or DGUOK or dGK). In total, 31 multi-case and single-case reports were reviewed in this study.
  34 in total

1.  Two patients with hepatic mtDNA depletion syndromes and marked elevations of S-adenosylmethionine and methionine.

Authors:  S Harvey Mudd; Conrad Wagner; Zigmund Luka; Sally P Stabler; Robert H Allen; Richard Schroer; Timothy Wood; Jing Wang; Lee-Jun Wong
Journal:  Mol Genet Metab       Date:  2011-11-12       Impact factor: 4.797

2.  Novel deoxyguanosine kinase gene mutations and viral infection predispose apparently healthy children to fulminant liver failure.

Authors:  Joseph T C Shieh; William E Berquist; Qing Zhang; Ping-Chieh Chou; Lee-Jun C Wong; Gregory M Enns
Journal:  J Pediatr Gastroenterol Nutr       Date:  2009-07       Impact factor: 2.839

3.  Neonatal liver failure due to deoxyguanosine kinase deficiency.

Authors:  Susana Nobre; Manuela Grazina; Francisco Silva; Carla Pinto; Isabel Gonçalves; Luísa Diogo
Journal:  BMJ Case Rep       Date:  2012-04-02

4.  New DGK gene mutations in the hepatocerebral form of mitochondrial DNA depletion syndrome.

Authors:  Michelangelo Mancuso; Silvio Ferraris; Jacklyn Pancrudo; Annette Feigenbaum; Julian Raiman; John Christodoulou; David R Thorburn; Salvatore DiMauro
Journal:  Arch Neurol       Date:  2005-05

5.  Novel mutation in DGUOK in hepatocerebral mitochondrial DNA depletion syndrome associated with cystathioninuria.

Authors:  Venu T Tadiboyina; Anthony Rupar; Paul Atkison; Annette Feigenbaum; Jonathan Kronick; Jian Wang; Robert A Hegele
Journal:  Am J Med Genet A       Date:  2005-06-15       Impact factor: 2.802

Review 6.  Mitochondrial DNA depletion syndromes: review and updates of genetic basis, manifestations, and therapeutic options.

Authors:  Ayman W El-Hattab; Fernando Scaglia
Journal:  Neurotherapeutics       Date:  2013-04       Impact factor: 7.620

7.  Muscle glycogenosis and mitochondrial hepatopathy in an infant with mutations in both the myophosphorylase and deoxyguanosine kinase genes.

Authors:  Michelangelo Mancuso; Massimiliano Filosto; Seiichi Tsujino; Costanza Lamperti; Sara Shanske; Michéle Coquet; Claude Desnuelle; Salvatore DiMauro
Journal:  Arch Neurol       Date:  2003-10

8.  Novel deoxyguanosine kinase gene mutations in the hepatocerebral form of mitochondrial DNA depletion syndrome.

Authors:  Taner Sezer; Figen Ozçay; Oya Balci; Füsun Alehan
Journal:  J Child Neurol       Date:  2014-01-14       Impact factor: 1.987

9.  The first founder DGUOK mutation associated with hepatocerebral mitochondrial DNA depletion syndrome.

Authors:  N Brahimi; M Jambou; E Sarzi; V Serre; N Boddaert; S Romano; P de Lonlay; A Slama; A Munnich; A Rötig; J P Bonnefont; A S Lebre
Journal:  Mol Genet Metab       Date:  2009-03-27       Impact factor: 4.797

10.  Molecular insight into mitochondrial DNA depletion syndrome in two patients with novel mutations in the deoxyguanosine kinase and thymidine kinase 2 genes.

Authors:  Liya Wang; Anna Limongelli; Maya R Vila; Franco Carrara; Massimo Zeviani; Staffan Eriksson
Journal:  Mol Genet Metab       Date:  2005-01       Impact factor: 4.797

View more
  1 in total

1.  Clinical and molecular characterization of three patients with Hepatocerebral form of mitochondrial DNA depletion syndrome: a case series.

Authors:  Ghazale Mahjoub; Parham Habibzadeh; Hassan Dastsooz; Malihe Mirzaei; Arghavan Kavosi; Laila Jamali; Haniyeh Javanmardi; Pegah Katibeh; Mohammad Ali Faghihi; Seyed Alireza Dastgheib
Journal:  BMC Med Genet       Date:  2019-10-29       Impact factor: 2.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.